JAK2 and MPL mutations in myeloproliferative neoplasms

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloproliferative disorders (MPDs), including polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF), are clonal hematopoietic stem cell disorders.
• These MPDs are characterized by the excessive proliferation of mature myeloid cells.
• The genetic underpinnings of MPDs remained largely unknown until the discovery of key mutations.

Purpose of the Study:

• To review the genetic basis of Philadelphia chromosome-negative MPDs.
• To discuss the role of somatic mutations in the pathogenesis of PV, ET, and PMF.
• To explore the therapeutic implications of identified genetic mutations in MPDs.

Main Methods:

• Review of scientific literature on MPD genetics.
• Analysis of studies identifying somatic mutations in JAK2 and MPL genes.
• Evaluation of in vitro and in vivo data on the transforming properties of these mutations.

Main Results:

• A recurrent mutation in the JAK2 tyrosine kinase (JAK2V617F) is found in over 90% of PV patients and a significant portion of ET and PMF patients.
• JAK2V617F is a constitutively active oncogene contributing to MPD development.
• Mutations in JAK2 exon 12 and MPL have also been identified in MPDs, leading to constitutive JAK2 signaling activation.

Conclusions:

• Somatic mutations, particularly in JAK2 and MPL, are central to the pathogenesis of MPDs.
• The identification of these oncogenic mutations provides crucial insights into MPD development.
• Understanding the genetics of MPDs opens avenues for targeted therapeutic strategies.